entertainment -WSS

entertainment

author：leisure time 2025-09-05 13:32:29 - browse：4

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

LONDON — A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, its developers said Monday, as the competition in the broader obesity medicine field pushes ahead.

The drug, survodutide, is being developed by the privately held German firm Boehringer Ingelheim and the Danish biotech Zealand Pharma. Zealand’s share price has doubled over the past year over the potential of the drug, and on Monday morning, shares jumped another 25%.

In the study, 83% of patients with a condition called MASH and who were treated with survodutide saw significant improvements in their disease compared to 18% of those who received placebo. The study met its primary endpoint of improvements in MASH after 48 weeks without the worsening of fibrosis, a scarring of the liver, the companies said. Secondary endpoints were also met, including an improvement in fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Would Medicare drug price negotiations stall in a shutdown?

hotspot

WSS

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Menendez indictment could see pharma lose a key ally

Gene editing the human germline: What are the risks?

Paxlovid should be available without a positive Covid test

Positive childhood experiences can help future health

STAT Virtual Event: How to Increase Diversity in Clinical Trials

explore

entertainment

Wikipedia

How one medical school became remarkably diverse

Methadone treatment changes are coming. Do they go far enough?

Alkermes shareholders re

Mindstrong's demise and the future of mental health care

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Medical records are filled with copy

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

United colonoscopy coverage change 'may cost lives,' doctors say

Shingles, which affected Dianne Feinstein, is on the rise

hotspot

Plastic surgeons increase patient psychiatric screenings

Listen: Who gets the credit for GLP

Kaiser Permanente unions announce official strike date

Menendez indictment could see pharma lose a key ally

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Orchard's therapy for neuron disease in children wins FDA approval

hotspot

hotspot

leisure time

knowledge